L'Oreal to close shu uemura operations in U.S.
This article was originally published in The Rose Sheet
Executive SummaryL'Oreal plans to shutter the Japanese makeup artistry brand in the U.S. and redirect resources to fuel its growth in the luxury market, according to a release. Shu uemura was a small part of the firm's luxury business, sold in the U.S. since 2004; L'Oreal will instead focus on its Lancome, Yves Saint Laurent, Giorgio Armani, Ralph Lauren,Kiehl's and fragrance brands, says L'Oreal USA luxury division President Carol Hamilton. Shu uemura "will continue its expansion in other parts of the world where it has seen significant growth and success." U.S. customers can continue to purchase products online at shuuemura.com
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.